Ocumetics Announces Successful Completion of Animal Study Q1 2024 First in Human Study Planned

(TheNewswire)

Calgary, Alberta TheNewswire - December 7, 2023 - Ocumetics Technology Corp. (" Ocumetics ") ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO), a pioneer in the field of ophthalmic innovation, proudly confirms the successful completion of its biocompatibility animal study, in preparation for its first-in-human study, anticipated to commence in Q1 2024 in the Dominican Republic.

The biocompatibility of the Ocumetics accommodating intraocular lens (the " Ocumetics Accommodating Lens" ) was evaluated by surgical implantation of two lenses into the eyes of rabbits. The first lens, the Ocumetics Accommodating Lens, was compared to the second lens, a commercially available monofocal intraocular lens (" IOL ") as a control. Results from this three-month animal study demonstrated that there were no biocompatibility or safety issues related to the Ocumetics Accommodating Lens when compared to the control IOL.

The study also evaluated the occurrence of anterior and posterior capsular opacification in the rabbit model over the three month period. There were no significant differences between the two IOL groups in terms of posterior capsular opacification and anterior capsular opacification at the end of the study.

Dr. Garth Webb, Founder and Chief Scientific Officer of Ocumetics, expressed enthusiasm about the outcomes, emphasizing, "Our primary focus in this study was to assess the surgical implantation performance of our revolutionary accommodating intraocular lens design. I am thrilled to report that the results not only met, but surpassed our expectations. This marks the realization of years of dedicated technological advancement."

Dr. Doyle Stulting, Chief Medical Officer of Ocumetics, shed light on the Ocumetics Accommodating Lens innovation, stating, "Our latest lens design caters to the needs of ophthalmologists by offering precise control during implantation, ensuring a gradual unfolding within the capsular bag. This new lens design was enthusiastically received by our Medical Advisory Board and should assure broad acceptance by ophthalmic surgeons immediately after US FDA marketing approval."

Dean Burns, President & CEO of Ocumetics, shared the roadmap ahead, "This successful study is a major milestone for Ocumetics, and a critical step for us to continue our journey towards US FDA approval. We anticipate initiating our first-in-human proof of concept studies in Q1 2024. These latest results are a testament to our team's skill and dedication, and we eagerly anticipate the launch of human trials."

About Ocumetics

Ocumetics Technology Corp. ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), headquartered in Calgary, Alberta, Canada, is an innovator in the field of ophthalmic technology, dedicated to developing and commercializing advanced vision correction solutions that enhance the quality of life for individuals worldwide.

Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry. In its pursuit of a next generation interocular lens solution, Ocumetics has developed the Ocumetics Accommodating Lens, an expandable intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses. It is designed to allow the eye's natural muscle activity to seamlessly shift focus from distance to intermediate to near.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dean Burns Dayton Marks

President and CEO Director

(817) 874-7564 (778) 347-2500

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

News Provided by TheNewsWire via QuoteMedia

Ocumetics Technology OTC:CA TSXV:OTC Emerging Tech Investing

OTC:CA

Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million

(TheNewswire)

Calgary, Alberta May 24, 2024 - TheNewswire . Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") ( TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it has completed the first tranche of the private placement of debentures previously announced by the Corporation on May 15, 2024.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Ocumetics Announces Offering of up to $4 million of Secured Convertible Debentures

(TheNewswire)

Calgary, Alberta TheNewswire - May 15, 2024. Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announces that it proposes to complete a non-brokered private placement of secured convertible debentures having an aggregate face value principal amount of up to $4,000,000 (the " Principal "). The debentures will be subject to an original issue discount of 6%, resulting in net available funds to the Corporation of up to $3,760,000 (the " Net Proceeds "). Debentures will bear interest at rate of 18% per annum, compounded annually. The Debentures will mature, and Principal and interest will be payable by the Corporation, on the date which is two years from the date of issue. The Corporation may prepay the indebtedness under the debentures at any time upon ninety (90) days prior written notice, without penalty.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Ocumetics Announces Extension of Private Placement

(TheNewswire)

Calgary, Alberta TheNewswire - December 21, 2023 - Ocumetics Technology Corp. (" Ocumetics " or the " Corporation ") (TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) is pleased to announce that the TSX Venture Exchange has granted a 15-day extension to close the Corporation's non-brokered private placement announced on November 15, 2023. The new closing deadline for the private placement is January 15, 2024.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

Ocumetics Announces December 20, 2023 Webinar regarding Successful Completion of Animal Study

(TheNewswire)

Ocumetics Technology Corp. (" Ocumetics ") ( TSXV:OTC) (OTC:OTCFF) (FRA:2QBO) a pioneer in the field of ophthalmic innovation, announces a webinar to discuss the successful completion of its biocompatibility animal study and its upcoming first-in-human study, anticipated to commence in Q1 2024 in the Dominican Republic

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less

PRINCIPAL TECHNOLOGIES ANNOUNCES CLOSING OF FIRST TRANCHE OF PRIVATE PLACEMENT

Principal Technologies Inc. (the " Company ") (TSXV: PTEC) (FSE: J07), is pleased to announce the closing of the first tranche (" Tranche 1 ") of its previously announced non-brokered private placement (the " Offering ") with one investor, MRPT Invest UG (" MRPT "), a company owned and controlled by Markus Mair . The Company issued a total of 4,000,000 units at $0.25 per unit for gross proceeds of $1,000,000 . Each unit (a " Unit ") will consist of one common share (a ' Share ") of the Company and one common share purchase warrant (a " Warrant "). Each Warrant entitles the holder to purchase one additional Share of the Company at $0.30 for a period of two (2) years from the date of closing. The Warrants are subject to a blocker term that prohibits exercise of the Warrants to the extent the holder would as a result of any exercise exceed 19.99% of then issued Shares.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Sona's Therapy Shows Significant Preclinical Efficacy in Second Cancer

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that its targeted hyperthermia therapy ("THT") demonstrated positive results in a second preclinical cancer model. Findings just presented at the 2024 STING & TLR Targeted Therapies Summit for immunotherapies in San Diego, California, show that Sona's THT achieved responses in a preclinical melanoma model equal to that which was recently reported from its triple negative breast cancer study. THT effectively treated melanoma tumors in all animals when administered on its own. Further, when THT was combined with doses of interleukin-2 ("IL-2"), a standard immunotherapy, a synergistic effect was shown whereby greater treatment response, measured by tumor volume reduction, was achieved in comparison to either approach alone.